TFX05-01
/ Shenzhen Yangli Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 28, 2022
A Study of TFX05-01 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=36 | Recruiting | Sponsor: Shenzhen Yangli Pharmaceutical Technology Co., Ltd
New P1/2 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1